CDK4/6 inhibitors: advances in breast cancer management

CDK4/6 inhibitors: advances in breast cancer management

Podkast av medthority

Join Dr Nadia Harbeck and Professor Alessandra Gennari in this podcast series on risk assessment and CDK4/6 inhibitors for the treatment of early brea...

Prøv gratis i 14 dager

Etter prøveperioden kun 99,00 kr / Måned.Avslutt når som helst.

Prøv gratis

Alle episoder

6 Episoder
episode Episode 6: The rapidly evolving treatment landscape for high-risk early breast cancer: Choosing the optimal treatment option artwork
Episode 6: The rapidly evolving treatment landscape for high-risk early breast cancer: Choosing the optimal treatment option

How might the early breast cancer treatment landscape change over the next 2 years? Dr Nadia Harbeck and Professor Michael Gnant review findings presented at ESMO 2023 and discuss approaches to optimal treatment selection in a rapidly evolving treatment landscape.

15. nov. 2023 - 13 min
episode Episode 5: The many definitions for ‘high risk of recurrence’ in early breast cancer: What should inform clinical practice? artwork
Episode 5: The many definitions for ‘high risk of recurrence’ in early breast cancer: What should inform clinical practice?

Recurrence risk is an important factor that must be considered in the treatment of early breast cancer. Dr Nadia Harbeck and Professor Michael Gnant discuss how recurrence risk and other factors can inform treatment selection.

15. nov. 2023 - 15 min
episode Episode 4: CDK4/6 inhibitors in the early breast cancer setting: Is the evidence clear? artwork
Episode 4: CDK4/6 inhibitors in the early breast cancer setting: Is the evidence clear?

Dr Nadia Harbeck and Professor Michael Gnant review the latest clinical trial evidence for CDK4/6 inhibitors in the early breast cancer setting and discuss what the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approval of abemaciclib means for clinicians and people with early breast cancer.

15. nov. 2023 - 12 min
episode Episode 3: Explanations for the divergent results of PALLAS/PENELOPE-B and monarchE trials artwork
Episode 3: Explanations for the divergent results of PALLAS/PENELOPE-B and monarchE trials

Dr Nadia Harbeck and Professor Alessandra Gennari review the completed clinical trials for CDK4/6 inhibitors in early breast cancer, namely PALLAS and PENELOPE-B for palbociclib and monarchE for abemaciclib. The divergent results for palbociclib and abemaciclib were unexpected, particularly as both proved effective in the metastatic setting and are now standard therapy for this indication. Dr Harbeck and Professor Gennari share their views on the possible reasons for the different outcomes with palbociclib and abemaciclib in early breast cancer.

22. sep. 2022 - 14 min
episode Episode 2: The RxPonder trial – identifying patients most likely to benefit from adjuvant therapy artwork
Episode 2: The RxPonder trial – identifying patients most likely to benefit from adjuvant therapy

Dr Nadia Harbeck and Professor Alessandra Gennari delve deeper into the RxPonder trial to explore the design and primary outcomes of the trial. Dr Harbeck and Professor Gennari discuss how RxPonder validated the use of the 21-gene expression assay as a tool to identify patients who could be spared chemotherapy.

22. sep. 2022 - 8 min
Enkelt å finne frem nye favoritter og lett å navigere seg gjennom innholdet i appen
Liker at det er både Podcaster (godt utvalg) og lydbøker i samme app, pluss at man kan holde Podcaster og lydbøker atskilt i biblioteket.
Bra app. Oversiktlig og ryddig. MYE bra innhold⭐️⭐️⭐️

Tilgjengelig overalt

Lytt til Podimo på telefonen, nettbrettet, datamaskinen eller i bilen!

Et univers av underholdning på lyd

Tusenvis av lydbøker og eksklusive podkaster

Ingen annonser

Ikke kast bort tid på å lytte til annonser når du lytter til Podimos innhold.

Prøv gratis i 14 dager

Etter prøveperioden kun 99,00 kr / Måned.Avslutt når som helst.

Eksklusive podkaster

Uten reklame

Gratis podkaster

Lydbøker

20 timer i måneden

Prøv gratis

Andre eksklusive podkaster

Populære lydbøker